# GSK Analysts See 3.5% Turnover Growth Ahead of Q3 Results

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/42375
Published: 2026-10-28T05:35:39.000Z
Updated: 2026-10-28T05:35:39.000Z
Section: Business

> The 15-analyst consensus also projects lower core operating profit and core EPS than a year earlier. GSK is due to release results at 3 a.m. ET Wednesday.

GSK is due to report third-quarter results Wednesday with a 15-analyst consensus projecting higher turnover but lower core operating profit and core earnings per share than a year earlier.

The consensus, effective Oct. 16, puts turnover at £8.842 billion, up about 3.5% from £8.547 billion in Q3 2025. The forecast includes £3.852 billion from specialty medicines, £2.624 billion from vaccines and £2.366 billion from general medicines.

Analysts project core operating profit of £2.929 billion, down from £2.985 billion a year earlier, a decline of about 1.9%. Core earnings per share are estimated at 50.4 pence, compared with 55 pence in Q3 2025, a decrease of about 8.4%.

GSK scheduled the results release for 3 a.m. ET (0700 UTC) Wednesday, Oct. 28. An investor and analyst call is set for 8 a.m. ET (1200 UTC).

The report will be GSK’s first quarterly results since the company announced a three-year savings program in July. GSK is targeting £1.9 billion in annual savings by 2029 and set program costs at £2.4 billion, including £2.1 billion in cash costs.

The company said the program is intended to fund investment in its late-stage portfolio and research and development. GSK Chief Executive Luke Miels said, “Savings will primarily be reinvested.”

GSK reaffirmed its 2026 guidance in July, projecting turnover growth of 3% to 5%. It expects core operating profit and core EPS growth of 7% to 9% at constant exchange rates.